InventisBio, Inc.

“In the following 10 to 20 years, the next R&D peak in small molecules lies in protein degradation; protein degraders will have a market worth at least $100bn,” Liqiang Fu, co-founder and chief te

The International Association for the Study of Lung Cancer’s World Conference on Lung Cancer from 7 to 10 September in San Diego will showcase the increased focus on targeted therapies, including risi

Innovent Biologics, Inc. and GenFleet Therapeutics on 21 August scored China’s first approval for a KRAS G12C inhibitor, the co-developed Dupert (fulzerasib), winning a head start over foreign and

Chinese drug makers have made both major cuts and additions to their R&D pipelines in recent months, including for antibody-drug conjugates (ADCs) amid increasingly fierce competition, a Scrip revie